Bristol Myers Squibb Reports First Phase 3 Data for KarXT
Bristol Myers Squibb reported preliminary results from the first Phase 3 study of KarXT in Alzheimer's-related psychosis.
Bristol Myers Squibb reported preliminary results from the first Phase 3 study of KarXT in Alzheimer's-related psychosis.